In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Jeanmougin M, Brodal HP, Dietrichson Pharo H, Vedeld HM, Lind GE(2022) PoDCall: positive droplet calling and normalisation of droplet digital PCR DNA methylation data Bioinformatics(in press) DOI 10.1093/bioinformatics/btac766, PubMed 36448696
Zavaleta E, Solis N, Palacios MI, Zevallos-Escobar LE, Corales EV, Bazo-Alvarez JC, Dominguez-Barrera C, Campos A, Wernhoff P, Ekstrøm PO, Møller P, Visnovska T, Hovig E, Balazar-Palacios J, Alvarez-Valenzuela K, Nakken S, Dominguez-Valentin M(2022) Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru Cancers (Basel), 14(22) DOI 10.3390/cancers14225603, PubMed 36428697
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH(2022) Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression J Immunol, 209(10), 2042-2053 DOI 10.4049/jimmunol.2200144, PubMed 36426942
Jeanmougin M, Brodal HP, Dietrichson Pharo H, Vedeld HM, Lind GE(2022) PoDCall: positive droplet calling and normalisation of droplet digital PCR DNA methylation data Bioinformatics(in press) DOI 10.1093/bioinformatics/btac766, PubMed 36448696
Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, Davis ZB, Merino A, Tuininga K, Wang H, Kumar A, Groff B, Witty A, Bonello G, Huffman J, Dailey T, Lee TT, Malmberg KJ, Walcheck B, Höpken U, Rehm A, Valamehr B, Miller JS(2022) Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma Nat Commun, 13(1), 7341 DOI 10.1038/s41467-022-35127-2, PubMed 36446823
Ghiasvand R, Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, Juzeniene A, Larsen IK, Green AC, Veierød MB, Robsahm TE(2022) Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study Int J Epidemiol(in press) DOI 10.1093/ije/dyac223, PubMed 36413027
